Denosumab and fracture risk in women with breast cancer

Lancet. 2015 Nov 21;386(10008):2057. doi: 10.1016/S0140-6736(15)00974-5. Epub 2015 Nov 20.

Authors

Paul de Boissieu¹, Thierry Trenque²

Affiliations

¹ Department for Pharmacovigilance and Pharmacoepidemiology, Reims University Hospital, and University of Reims Champagne-Ardenne, Faculty of Medecine, Reims, France.
² Department for Pharmacovigilance and Pharmacoepidemiology, Reims University Hospital, and University of Reims Champagne-Ardenne, Faculty of Medecine, Reims, France. Electronic address: [email protected].

PMID: 26700392
DOI: 10.1016/S0140-6736(15)00974-5

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Breast Neoplasms / complications*
Female
Fractures, Bone*
Humans

Substances

Antibodies, Monoclonal, Humanized